STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ABMD ABIOMED INCORPORATED StockScouter® Report

2

StockScouter® Score

ABIOMED INCORPORATED, a mid cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated rapidly compared to earnings growth in the past three years. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • The ratio of ABMD’s forward price-to-earnings multiple to its estimated growth rate is well above the average of comparably-sized companies in the StockScouter universe. Negative
  • The multi-period measure of relative price change and consistency is well below average. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be in favor, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 60% done.
Progress: 40% done.
Low
High

Core Model Grades

B
D
F
F

Previous Ratings

3
5
4